Ovarian cancer: An overview

American Family Physician

Volumn 80, Issue 6, 2009, Pages 609-616

  Roett, Michelle A ^a,b   Evans, Patricia ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b Fort Lincoln Family Medicine Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL; STROMAL CELL DERIVED FACTOR 1;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FAMILY; CANCER GRADING; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EPITHELIUM CELL; EPITHELIUM TUMOR; FAMILY HISTORY; GENE STRUCTURE; GENETIC COUNSELING; GENETIC DISORDER; GERM CELL; HERITABILITY; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; RISK FACTOR; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; TUMOR GENE; WOMEN'S HEALTH;

EID: 70349222742     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. American Cancer Society. Cancer facts & figures 2008. Atlanta, Ga.: American Cancer Society; 2008.
2. Centers for Disease Control and Prevention. United States cancer statistics: 1999-2005 cancer incidence and mortality data. U.S. Department of Health and Human Services. http://www.cdc.gov/uscs. Accessed February 26, 2009.
3. Ries LA, Melbert D, Krapcho M, et al., eds. SEER cancer statistics review, 1975-2004. Bethesda, Md.: National Cancer Institute; 2007. http://seer.cancer.gov/csr/1975-2004. Accessed March 2, 2009.
4. Grody WW, Walter WN. Molecular diagnosis of genetic diseases. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. Philadelphia, Pa.: Saunders; 2007: 1334-1335.
5. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919-932.
6. Chen LM, Karlan BY. Early detection and risk reduction for familial gynecologic cancers. Clin Obstet Gynecol. 1998;41(1):200-214.
7. Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(1):42-46. (Pubitemid 36110156)
8. Prentice RL, Thomson CA, Caan B, et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst. 2007;99(20):1534-1543. (Pubitemid 351767234)
9. Vo C, Carney ME. Ovarian cancer hormonal and environmental risk effect. Obstet Gynecol Clin North Am. 2007;34(4):687-700. (Pubitemid 350182430)
10. Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology. 2004;15(1):100-104. (Pubitemid 40417003)
11. U.S. Preventive Services Task Force. Screening for ovarian cancer: recommendation statement. U.S. Preventive Services Task Force. Am Fam Physician. 2005;71(4):759-762.
12. Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 2000;66(4):1259-1272. (Pubitemid 30468783)
13. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002:275-284.
14. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement [published correction in Ann Intern Med. 2005;143(7):547]. Ann Intern Med. 2005;143(5):355-361.
15. Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol. 1992;80(1):19-26.
16. Huncharek M, Muscat J, Onitilo A, Kupelnick B. Use of cosmetic talc on contraceptive diaphragms and risk of ovarian cancer: a meta-analysis of nine observational studies. Eur J Cancer Prev. 2007;16(5):422-429. (Pubitemid 47550002)
17. Young RH, Clement PB, Scully RE. The ovary. In: Sternberg SS, Antonioli DA, Mills SE, Carter D, Oberman HA, eds. Diagnostic Surgical Pathology. 2nd ed. New York, NY: Raven Press; 1994.
18. Crum CP. The female genital tract. In: Kumar V, Fausto N, Abbas AK, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadephia, Pa.: Elsevier, Inc; 2005.
19. Han LY, Coleman RL. Ovarian cancer staging. Oper Tech Gen Surg. 2007;9(2):53-60.
20. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2000:981-1057.
21. Pecorrelli S, Creasman WT, Pettersson F, Benedet JL. Shaperd JH, eds. FIGO annual report on the results of treatment in gynecologic cancer. J Epidemiol Biostat. 1998;3:75-102.
22. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31(5):539-557.
23. Thigpen T, Brady M, Omura G, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993;71(2 suppl):606-614. (Pubitemid 23021258)
24. International Federation of Gynecology and Obstetrics. The new FIGO stage grouping for primary carcinoma of the ovary (1985). Gynecol Oncol. 1986;25:383-385.
25. Smith LH, Morris CR, Yasmeen S, Parikh-Patel A, Cress RD, Romano PS. Ovarian cancer: can we make the clinical diagnosis earlier? Cancer. 2005;104(7):1398-1407. (Pubitemid 41356155)
26. Ryerson AB, Eheman C, Burton J, et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol. 2007;109(5):1053-1061. (Pubitemid 46685945)
27. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109(2):221-227. (Pubitemid 46106236)
28. Drake J. Diagnosis and management of the adnexal mass. Am Fam Physician. 1998;57(10):2471-2476,2479-2480.
29. American College of Obstetricians and Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol. 2002;100(6):1413-1416.
30. Takeshima N, Hirai Y, Umayahara K, Fujiwara K, Takizawa K, Hasumi K. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol Oncol. 2005;99(2):427-431. (Pubitemid 41502856)
31. Barney SP, Muller CY, Bradshaw KD. Pelvic masses. Med Clin North Am. 2008;92(5):1143-1161.
32. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol. 2007;110(1): 201-214.
33. Funt SA, Hann LE. Detection and characterization of adnexal masses. Radiol Clin North Am. 2002;40(3):591-608.
34. Komatsu T, Konishi I, Madai M, et al. Adnexal masses: transvaginal US and gadolinium-enhanced MR imaging assessment of intratumoral structure. Radiology. 1996;198(1):109-115. (Pubitemid 26008250)
35. Sevinc A, Adli M, Kalender ME, Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol. 2007;8(12):1054-1055. (Pubitemid 350182965)
36. Morrison J, Swanton A, Collins S, Kehoe S. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2007;(4):CD005343. (Pubitemid 351805181)
37. Gadducci A, Sartori E, Maggino T, et al. Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study. Int J Gynecol Cancer. 1997;7(6):445-450. (Pubitemid 28020705)
38. Stirling D, Evans DG, Pichert G, et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics system. J Clin Oncol. 2005;23(24):5588-5596. (Pubitemid 46300153)
39. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327-340.
40. Finch A, Beiner M, Lubinski J, et al., for the Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296(2):185-192.
41. Chen LM, Yang KY, Little SE, Cheung MK, Caughey AB. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol. 2007;110(1):18-25. (Pubitemid 47015695)
42. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch repair genes. Int J Cancer. 1999;81(2):214-218. (Pubitemid 29144749)
43. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast and ovarian. V.I. 2008. http://www.nccn.org/professionals/physician-gls/PDF/genetics-screening.pdf (subscription required). Accessed March 2, 2009.
44. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296(12):1507-1517.
45. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20(5):1260-1268. (Pubitemid 34177432)
46. Gaarenstroom KN, van der Hiel B, Tollenaar RA, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer. 2006;(16 suppl 1):54-59.